Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891484912> ?p ?o ?g. }
- W2891484912 endingPage "178" @default.
- W2891484912 startingPage "167" @default.
- W2891484912 abstract "Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice." @default.
- W2891484912 created "2018-09-27" @default.
- W2891484912 creator A5007013927 @default.
- W2891484912 creator A5018381770 @default.
- W2891484912 creator A5021656597 @default.
- W2891484912 creator A5035004148 @default.
- W2891484912 creator A5038585908 @default.
- W2891484912 creator A5040987010 @default.
- W2891484912 creator A5048627921 @default.
- W2891484912 creator A5052388889 @default.
- W2891484912 creator A5053052330 @default.
- W2891484912 creator A5055075817 @default.
- W2891484912 creator A5063290790 @default.
- W2891484912 creator A5069616282 @default.
- W2891484912 creator A5072584423 @default.
- W2891484912 creator A5089871365 @default.
- W2891484912 date "2018-09-05" @default.
- W2891484912 modified "2023-10-16" @default.
- W2891484912 title "MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges" @default.
- W2891484912 cites W1142635415 @default.
- W2891484912 cites W1537479709 @default.
- W2891484912 cites W1583484677 @default.
- W2891484912 cites W1758548132 @default.
- W2891484912 cites W1965705450 @default.
- W2891484912 cites W1971344938 @default.
- W2891484912 cites W1994465394 @default.
- W2891484912 cites W1998747830 @default.
- W2891484912 cites W2011570504 @default.
- W2891484912 cites W2013816626 @default.
- W2891484912 cites W2025634492 @default.
- W2891484912 cites W2033071625 @default.
- W2891484912 cites W2042723765 @default.
- W2891484912 cites W2045510579 @default.
- W2891484912 cites W2062299448 @default.
- W2891484912 cites W2066343654 @default.
- W2891484912 cites W2073618702 @default.
- W2891484912 cites W2074095225 @default.
- W2891484912 cites W2089548634 @default.
- W2891484912 cites W2092033495 @default.
- W2891484912 cites W2094354684 @default.
- W2891484912 cites W2096287682 @default.
- W2891484912 cites W2096681571 @default.
- W2891484912 cites W2098442878 @default.
- W2891484912 cites W2101922439 @default.
- W2891484912 cites W2105100844 @default.
- W2891484912 cites W2105528101 @default.
- W2891484912 cites W2106816824 @default.
- W2891484912 cites W2107731988 @default.
- W2891484912 cites W2111229057 @default.
- W2891484912 cites W2122404743 @default.
- W2891484912 cites W2124736921 @default.
- W2891484912 cites W2130737006 @default.
- W2891484912 cites W2131981377 @default.
- W2891484912 cites W2135396269 @default.
- W2891484912 cites W2135947790 @default.
- W2891484912 cites W2141136499 @default.
- W2891484912 cites W2144941946 @default.
- W2891484912 cites W2145489645 @default.
- W2891484912 cites W2146803439 @default.
- W2891484912 cites W2154146769 @default.
- W2891484912 cites W2154526619 @default.
- W2891484912 cites W2158681922 @default.
- W2891484912 cites W2158751879 @default.
- W2891484912 cites W2165438710 @default.
- W2891484912 cites W2165871546 @default.
- W2891484912 cites W2171418517 @default.
- W2891484912 cites W2262031615 @default.
- W2891484912 cites W2282164829 @default.
- W2891484912 cites W2288710734 @default.
- W2891484912 cites W2300412351 @default.
- W2891484912 cites W2330247213 @default.
- W2891484912 cites W2345717877 @default.
- W2891484912 cites W2346904924 @default.
- W2891484912 cites W2505666614 @default.
- W2891484912 cites W2516799566 @default.
- W2891484912 cites W2520647351 @default.
- W2891484912 cites W2525432357 @default.
- W2891484912 cites W2574800639 @default.
- W2891484912 cites W2599750069 @default.
- W2891484912 cites W2610403529 @default.
- W2891484912 cites W2768388636 @default.
- W2891484912 cites W2778283729 @default.
- W2891484912 cites W2787702713 @default.
- W2891484912 cites W2787816121 @default.
- W2891484912 cites W2791209168 @default.
- W2891484912 cites W4255148874 @default.
- W2891484912 cites W78554930 @default.
- W2891484912 doi "https://doi.org/10.1093/neuonc/noy132" @default.
- W2891484912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6374759" @default.
- W2891484912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30189035" @default.
- W2891484912 hasPublicationYear "2018" @default.
- W2891484912 type Work @default.
- W2891484912 sameAs 2891484912 @default.
- W2891484912 citedByCount "149" @default.
- W2891484912 countsByYear W28914849122019 @default.
- W2891484912 countsByYear W28914849122020 @default.
- W2891484912 countsByYear W28914849122021 @default.
- W2891484912 countsByYear W28914849122022 @default.